Front Page

Previous Story

Next Story

NIH Record vertical blue bar column separator

Rohrbaugh Named Director of OTT

Dr. Mark L. Rohrbaugh has been named director of the Office of Technology Transfer in the Office of Intramural Research, OD. He will oversee the patenting and licensing of NIH inventions and contribute to intramural and extramural technology transfer policy at NIH and HHS.

Dr. Mark Rohrbaugh
"We are delighted that Dr. Rohrbaugh will be taking the helm of the OTT at this critical time for technology transfer, as more and more of our basic science discoveries are translated into effective preventions, diagnostics and treatments for human disease," said NIH director Dr. Elias Zerhouni, who made the appointment.

Rohrbaugh takes the helm of the most successful technology licensing program in the federal government in terms of commercialized products, as well as the lead office for technology transfer within the department. NIH technology transfer efforts have had an increasingly important role in improving the nation's health through licensing and other collaborations that have helped bring the results of NIH and FDA laboratory research to the public.


During the past 10 years, NIH executed more than 1,800 licenses to inventions made by its intramural research program resulting in more than $350 million in royalties. More importantly, these efforts have resulted in the development, by its commercial partners, of more than 20 life-saving drugs, vaccines and diagnostics and more than 100 other biomedical products.

Rohrbaugh started his career at NIH in 1991 as scientific review administrator for the allergy, immunology, and transplantation research committee, NIAID. In 1995, he moved from NIAID's extramural program to the institute's Office of Technology Development, serving as director of that office from 1997 to 2001. Before joining NIH, Rohrbaugh conducted molecular and cell biology research as a McKnight Foundation postdoctoral fellow at the University of Minnesota and as a research and senior scientist at two biotechnology companies in Minneapolis.


Up to Top